
cis-Urocanic acid
CAS No. 7699-35-6
cis-Urocanic acid( (Z)-Urocanic acid | cis-UCA | (E)-Urocanic acid | (Z)-Imidazole-4-acrylic acid | (Z)-3-(1H-Imidazol-5-yl)acrylic acid )
Catalog No. M26118 CAS No. 7699-35-6
cis-Urocanic acid is a 5-HT2A receptor agonist (Kd: 4.6 nM). It is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 417 | Get Quote |
![]() ![]() |
10MG | 615 | Get Quote |
![]() ![]() |
25MG | 963 | Get Quote |
![]() ![]() |
50MG | 1305 | Get Quote |
![]() ![]() |
100MG | 1755 | Get Quote |
![]() ![]() |
500MG | 3501 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product Namecis-Urocanic acid
-
NoteResearch use only, not for human use.
-
Brief Descriptioncis-Urocanic acid is a 5-HT2A receptor agonist (Kd: 4.6 nM). It is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.
-
Descriptioncis-Urocanic acid is a 5-HT2A receptor agonist (Kd: 4.6 nM). It is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.(In Vitro):Treatment with 100 μg/mL cis-Urocanic acid completely suppresses IL-6 and IL-8 secretion decreases caspase-3 activity and improves cell viability against UV-B irradiation. No significant effects on IL-6 or IL-8 secretion, caspase-3 activity, or viability of the non-irradiated cells are observed with 100 μg/mL cis-Urocanic acid in both cell types .
-
In VitroTreatment with 100 μg/mL cis-Urocanic acid (cis-UCA) completely suppresses IL-6 and IL-8 secretion, decreases caspase-3 activity, and improves cell viability against UV-B irradiation. No significant effects on IL-6 or IL-8 secretion, caspase-3 activity, or viability of the non-irradiated cells are observed with 100 μg/mL cis-Urocanic acid in both cell types. The 5000 μg/mL concentration is toxic Cell Viability Assay Cell Line:Human corneal epithelial cells (HCE-2) and human conjunctival epithelial cells (HCECs)Concentration:10, 100, 1,000, and 5,000 μg/mL Incubation Time:24, 48, or 72 hours Result:Treatment with 100 μg/mL completely suppressed IL-6 and IL-8 secretion, decreased caspase-3 activity, and improved cell viability against UV-B irradiation. No significant effects on IL-6 or IL-8 secretion, caspase-3 activity, or viability of the non-irradiated cells were observed with 100 μg/mL in both cell types.
-
In Vivo——
-
Synonyms(Z)-Urocanic acid | cis-UCA | (E)-Urocanic acid | (Z)-Imidazole-4-acrylic acid | (Z)-3-(1H-Imidazol-5-yl)acrylic acid
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
RecptorAlkyl-Chain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number7699-35-6
-
Formula Weight138.126
-
Molecular FormulaC6H6N2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 50 mg/mL (362.00 mM)
-
SMILESOC(=O)\C=C/c1cnc[nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
molnova catalog



related products
-
Terfenadine
Terfenadine is a histamine H1-receptor antagonist, which blocks HERG and KATP (KIR6) channels.
-
Cinitapride
Cinitapride is a gastroprokinetic agent. It slows the actions of the muscles to reduce the symptoms of conditions such as acid reflux, delayed gastric emptying, and ulcer dyspepsia.
-
BIMU 8
BIMU 8 is a selective agonist of 5-HT4 with EC50s of 18 nM, 77 nM, and 540 nM for wild-type 5HT4 receptor, T3.36A, and W6.48A mutant 5-HT4.